Literature DB >> 15988913

Activity of epothilones.

Ada Kolman1.   

Abstract

Epothilones represent a novel class of anticancer drugs which inhibit the cell cycle and strongly influence cell division. The biological activity of epothilones is associated with their capacity to bind to the protein tubulin of microtubules and to disturb the dynamic equilibrium between microtubule assembling and disassembling. Consequently, in dividing cells, it leads to mitotic arrest and to apoptotic cell death. A number of epothilones demonstrate a potent inhibitory effect on cell proliferation in human tumor cell lines, as well as antitumor activity in experimental animals bearing human tumor xenografts. This review will focus on the recent preclinical studies of the in vitro and in vivo activities of four epothilones, EPO-906, BMS-247550, KOS-862 and BMS-310705. Several epothilones are undergoing clinical evaluation and are promising candidates for advanced cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15988913

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  8 in total

1.  Different phosphorylation states of the anaphase promoting complex in response to antimitotic drugs: a quantitative proteomic analysis.

Authors:  Judith A J Steen; Hanno Steen; Ann Georgi; Kenneth Parker; Michael Springer; Marc Kirchner; Fred Hamprecht; Marc W Kirschner
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-17       Impact factor: 11.205

2.  A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors.

Authors:  J Paul Monk; Miguel Villalona-Calero; Joe Larkin; Greg Otterson; David S Spriggs; Alison L Hannah; Gillian F Cropp; Robert G Johnson; Martee L Hensley
Journal:  Invest New Drugs       Date:  2011-08-09       Impact factor: 3.850

3.  Exposure-response relationship of the synthetic epothilone sagopilone in a peripheral neurotoxicity rat model.

Authors:  Alessia Chiorazzi; Joachim Höchel; Detlef Stöckigt; Annalisa Canta; Valentina Alda Carozzi; Cristina Meregalli; Federica Avezza; Luca Crippa; Barbara Sala; Cecilia Ceresa; Norberto Oggioni; Guido Cavaletti
Journal:  Neurotox Res       Date:  2011-12-22       Impact factor: 3.911

Review 4.  Present and future evolution of advanced breast cancer therapy.

Authors:  Ricardo H Alvarez
Journal:  Breast Cancer Res       Date:  2010-10-22       Impact factor: 6.466

5.  Design, synthesis and biological evaluation of bridged epothilone D analogues.

Authors:  Qiao-Hong Chen; Thota Ganesh; Peggy Brodie; Carla Slebodnick; Yi Jiang; Abhijit Banerjee; Susan Bane; James P Snyder; David G I Kingston
Journal:  Org Biomol Chem       Date:  2008-11-06       Impact factor: 3.876

Review 6.  Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone.

Authors:  Edgardo Rivera; Henry Gomez
Journal:  Breast Cancer Res       Date:  2010-10-22       Impact factor: 6.466

Review 7.  Natural Compounds as Modulators of Cell Cycle Arrest: Application for Anticancer Chemotherapies.

Authors:  Natalia Bailon-Moscoso; Gabriela Cevallos-Solorzano; Juan Carlos Romero-Benavides; Maria Isabel Ramirez Orellana
Journal:  Curr Genomics       Date:  2017-04       Impact factor: 2.236

8.  Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.

Authors:  George Fountzilas; Vassiliki Kotoula; Dimitrios Pectasides; George Kouvatseas; Eleni Timotheadou; Mattheos Bobos; Xanthipi Mavropoulou; Christos Papadimitriou; Eleni Vrettou; Georgia Raptou; Angelos Koutras; Evangelia Razis; Dimitrios Bafaloukos; Epaminontas Samantas; George Pentheroudakis; Dimosthenis V Skarlos
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.